Probatebeta
Target

NTRK1

High affinity nerve growth factor receptor

As of the edition of 20 October 2026, NTRK1 (high affinity nerve growth factor receptor, UniProt P04629) has 18 drugs tested at it and 21 companies on the list, 7 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P04629
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
66
Disease areas
Cancer; Digestive system; Lungs and airways; Nervous system; Hormones; Skin and connective tissue; Urinary and reproductive; Eye
Registered trials of its drugs
385

Drugs at this target

StatusCount
Marketed5
Active2
Went quiet4
Stopped5
Status not established2
Total18
DrugStatusFurthest phaseUS protection
RegorafenibMarketedPhase 4Ends 2032
EntrectinibMarketedPhase 4Ends 2037
CenegerminMarketedPhase 4Ends 2030
LarotrectinibMarketedPhase 4Ends 2036
TaletrectinibMarketedPhase 3Ends 2033
Nerve growth factorStoppedPhase 4none listed
MilciclibStoppedPhase 2none listed
SelitrectinibStatus not establishedPhase 1none listed
E2511ActivePhase 1none listed
PegcantratinibWent quietPhase 2none listed
GZ-389988Went quietPhase 2none listed
AZD-6918StoppedPhase 1none listed

12 of 18 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B5
Engaged7
Undetermined2
Total on the list21
Three companies on route A or B, with the route only
CompanyRoute
Tiziana Life SciencesRoute A
AstraZenecaRoute A
SanofiRoute A

The other 18 companies at NTRK1

In the product

21 companies in all; 18 are not named here, and no score is.

See the 21 companies at NTRK1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at NTRK1

Other targets in cancer

Companies holding approvals at NTRK1